AAPL vs PFE: Which Is the Better Buy?

Side-by-side comparison of Apple Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Apple Inc. · Technology
$260.88
+135.9% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
AAPL has more upside to fair value (+135.9%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric AAPL PFE
Current Price $260.88 $26.91
Fair Value Estimate $615.48 $35.00
Upside to Fair Value +135.9% +30.1%
Market Cap $3,834.4B $153.0B
Forward P/E 32.6x 9.5x
EV / EBITDA 25.4x 13.8x
Price / Sales 8.8x 2.4x
Price / FCF 31.1x 16.8x
Revenue Growth YoY +40.3% -1.6%
Gross Margin 47.3% 70.3%
Operating Margin 32.4% 24.7%
Return on Equity 159.9% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 3.21% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
AAPL — Apple Inc.
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services with a strong brand and durable competitive advantages. The business quality is high, demonstrated by exceptional profitability metrics including a 159.9% return on equity, 40.3% revenue growth year-over-year, and 53.3% earnings growth year-over-year. Despite these fundamentals, the stock is cu…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric AAPL PFE
Zone Low $461.61 $25.00
Zone High $523.16 $29.00
In Buy Zone? Yes Yes
← AAPL Research    PFE Research →    All Research